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summary
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by heterogeneous clinical mani-
festations involving virtually the entire body. The pain in SLE can have different causes. The SLE classification 
criteria include mainly the musculoskeletal manifestations of pain, which are commonly reported as initial 
symptoms of SLE, such as arthralgia, arthritis and/or myalgia. Chronic widespread pain, which is typical of 
fibromyalgia (FM), is frequently associated with SLE. The aim of this review is to describe widespread pain 
and fatigue in SLE, and the association of SLE and FM. Although secondary FM is not correlated with the 
disease activity, it may interfere with the daily activities of SLE patients. Therefore it is necessary to identify 
its symptoms and treat them promptly to improve the quality of life of patients. In conclusion, it is essential 
to identify the origin of pain in SLE in order to avoid dangerous over-treatment in patients with co-existing 
widespread pain and FM.
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n	 INTRODUCTION
Shronic widespread pain and fibromyal-gia (FM) are frequently associated with 
rheumatic autoimmune diseases. FM co-
exists in 30% of patients with rheumatoid 
arthritis, 50% of those with Sjögren syn-
drome (SjS), and 30% of those with sys-
temic lupus erythematosus (SLE) (1). SLE 
is an autoimmune disease characterized by 
heterogeneous clinical manifestations in-
volving skin, joints, kidneys, heart, nervous 
system and virtually any other organ in the 
body. 
Its association with FM, which is a syn-
drome characterized by chronic widespread 
pain and symptoms such as fatigue and 
sleep disturbances, can sometimes compli-
cate the evaluation of pain, which should 
be differentiated from SLE-related dis-
ease activity or chronic damage. The most 
widely used indices to measure objectively 
the disease activity in SLE are the British 
isles lupus assessment group (BILAG) in-
dex, the European consensus lupus activity 
measurement (ECLAM), and the systemic 
lupus erythematosus disease activity index 
(SLEDAI), none of which are specifically 
meant to evaluate musculoskeletal pain 
per se. The health-related quality of life 
(HRQoL) of SLE patients can be assessed 
by means of questionnaires, such as the 
short form 36 (SF-36) (2), and the patient 
acceptable symptom state, which is a sim-
ple questionnaire to assess well-being in 
patients with various rheumatic conditions, 
including SLE (3). 
The classification criteria started to be de-
veloped already in the early 1970s, where 
the criteria currently in use were introduced 
by the American College of Rheumatology 
(ACR) in 1982, and revised in 1997 (4). 
In 2012, the Systemic Lupus International 
Collaborating Clinics (SLICC) group pro-
posed a new set of criteria that also include 
less specific clinical manifestations that 
are frequently reported by SLE patients 
(5), with pain being mainly confined to the 
musculoskeletal system. The aim of this 
review is to describe widespread pain and 
fatigue in SLE, and the association of SLE 
and FM.
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n	 PATHOGENESIS
Pain in SLE can be attributable to various 
causes (e.g. inflammatory, neuropathic, 
and central pain), although it is most often 
associated with joint inflammation. The 
ACR SLE classification criteria refer to 
the presence of synovitis in two or more 
joints (characterized by swelling or effu-
sion), whereas the proposed SLICC criteria 
extend the definition of musculoskeletal in-
volvement to inflammatory arthralgia (ten-
derness in two or more joints with morning 
stiffness lasting at least 30 minutes) (4, 5). 
Joint manifestations can precede other SLE 
features, and typically consist in arthralgia 
and/or non-erosive, non-deforming arthri-
tis. However, in same cases, arthritis can 
lead to reducible deformities, known as 
Jaccoud’s arthropathy (6). 
Like in other inflammatory joint diseases, 
the pathogenic mechanisms of inflamma-
tory arthritis in SLE involve the production 
of cytokines such as interleukin (IL)-6, 
IL-17, interferon-α, IL-18, tumor necro-
sis factor-α and B lymphocyte stimulator. 
These inflammatory mediators play a cru-
cial role in the differentiation, maturation 
and activation of the immunocompetent 
cells involved in the local inflammatory 
process and tissue injury (7). 
Another source of pain is lupus headache, 
which is reported by 32-66% of SLE pa-
tients and can have various causes, includ-
ing neuropsychiatric SLE (NPSLE) (8-10). 
In NPSLE patients, a close association was 
identified between cognitive impairment 
and depression, pain and fatigue, but the 
underlying causes are still unclear. Auto-
antibodies cross-reacting with DNA and 
N-methyl-D-aspartate receptors, anti-en-
dothelial antibodies and anti-phospholipid 
antibodies are the most common factors as-
sociated with the pathogenesis of NPSLE 
(11, 12). Depression, pain, and fatigue may 
also sometimes reflect an underlying cen-
tral nervous system (CNS) disorder (13). 
Abdominal pain is reported by 8-40% of 
SLE patients (14), and may due to vari-
ous causes, including mesenteric vasculitis 
and pancreatitis (15). The association of 
pain and cutaneous lupus has been recently 
evaluated and it was found that the pain 
was more intense in patients with vasculitic 
and bullous lesions, followed by patients 
with oral ulcers (16). 
One of the first symptoms reported by SLE 
patients is pain resulting from musculo-
skeletal involvement (17), which affects 
approximately 50-90% of patients during 
the course of the disease (18). 
Chronic widespread pain, which affects 
5-10% of the general population (19), is 
reported by 65-80% of SLE patients (20, 
21). Central sensitization, characterized 
by an enhanced peripheral nociceptive in-
put and abnormal central pain processing 
of the CNS, seems to be the pathogenic 
mechanism causing hyperalgesia and al-
lodynia (22). Fatigue is the most common 
constitutional symptom associated with 
pain in SLE patients (23) and has a preva-
lence ranging from 50% to over 80% (24). 
It can also be the most debilitating symp-
tom (25,26), although it is not associated 
with the disease activity or the chronic or-
gan damage, but only with anemia. 
n	 PUBLISHED FINDINGS
Chronic widespread pain is the cornerstone 
of FM, which is characterized by tender-
ness on palpation of at least 11/18 tender 
points (TPs) (27). FM is also characterized 
by fatigue and multiple associated symp-
toms, such as sleep, mood and neurocog-
nitive disorders, as indicated by the 2010 
ACR classification criteria (28).
A number of studies investigated the prev-
alence of FM in SLE patients, and evalu-
ated how concomitant FM can influence 
the symptoms and the activity of SLE. The 
prevalence of FM varies depending on the 
ethnic group suggesting a possible influ-
ence of geographical, psychological and 
socio-cultural factors. Its prevalence was 
found to be 8.2% in a cohort of Indian SLE 
patients, 9.5% in Mexican SLE patients, 
10% in a Spanish cohort, and 25% among 
Turkish SLE patients (29-32). 
Various authors studied the prevalence 
of FM in LES patients. Morand et al. re-
ported a 25.3% prevalence in a cohort of 
N
n-
co
mm
er
cia
l u
se
 on
ly
Reumatismo 1/2014 35
reviewPain and systemic lupus erythematosus
87 SLE patients (33), while Middleton et 
al. reported a 22% prevalence in a group of 
102 SLE patients (34). However, although 
23% of the patients in the latter study pre-
sented widespread pain, they did not meet 
the 1990 ACR classification criteria. The 
authors reported that SLE patients with 
concomitant FM have significantly more 
frequent and severe symptoms, but no sig-
nificant difference in SLE activity mea-
sures was identified between patients with 
or without FM (34).
Similarly, the presence of FM in 21% of a 
Canadian cohort of 119 SLE patients did 
not correlate with the disease activity and 
the damage indices, but it was closely cor-
related with the quality of life which was 
measured on the basis of the SF-36 ques-
tionnaire (35). Friedman et al. confirmed 
that there was no correlation between the 
clinical scores of disease activity, disease 
damage, specific organ dysfunction and 
concomitant FM, which was diagnosed 
only in 5% of SLE patients (36).
Taylor et al. investigated whether FM was 
more frequent in patients who complained 
fatigue, and found that only 10% of these 
patients fulfilled the criteria for FM (37).
An Israeli group found that SLE patients 
with FM had significantly lower HRQoL 
scores than those without FM (38). In 
2005, Akkasilpa et al. evaluated the asso-
ciation between tender point positivity and 
health status in a group of 173 SLE patients 
using the health assessment questionnaire 
(HAQ): 17.3% of the patients had ≥11 TPs 
and the number of TPs was significantly 
associated with their HAQ scores (39).
We have recently analyzed the prevalence 
of widespread pain and fatigue in a group 
of Italian patients with SLE or SjS. FM was 
diagnosed in a significantly higher percent-
age of SLE patients (33% vs 18%). More-
over, the SLE patients showed a correlation 
between HAQ scores and fatigue and pain, 
whereas no correlation was found between 
the associated FM and the disease activity 
indices (21).
Grafe et al. observed that FM was more 
frequent in SLE patients (prevalence of 
16.7%) than in patients with cutaneous lu-
pus. The patients with SLE and concomi-
tant FM also reported significantly more 
often symptoms such as headache, morn-
ing stiffness, diffuse alopecia, and arthral-
gia (40).
Pain is associated with perceptions of re-
duced physical functioning and coping re-
sources, and higher levels of anxiety and 
depression. Consequently SLE patients 
need psychosocial interventions in order 
to relieve pain and distress and improve 
coping skills (41). Pain coping cognitions, 
such as self-efficacy for pain control and 
pain catastrophizing, may influence symp-
toms such as pain, stiffness, fatigue, and 
psychological distress in SLE patients. Re-
cent data demonstrates that patients with 
low levels of self-efficacy for pain control 
and/or high levels of pain catastrophizing 
reported more physical symptoms and psy-
chological distress, and highlights the im-
portance of assessing coping constructs in 
SLE patients (42).
Apart from FM, pain can interfere with the 
quality of life, and the SLE patients who 
experience the highest levels of pain also 
report stiffness and fatigue. Pain can also 
cause functional limitations that lead to a 
significant economic burden on the society 
as a whole (43). The working productiv-
ity of SLE patients with the highest levels 
of pain is lower than that of SLE patients 
with less pain (44), and pain also predicted 
negative energy levels (45). Pettersson et 
al. found that the most frequently reported 
symptoms by SLE patients are fatigue, pain 
and musculoskeletal distress, all of which 
are related to low HRQoL scores, although 
only fatigue has an impact on both mental 
and physical components (46).
Table I - Common symptoms of systemic lupus 
erythematosus and fibromyalgia.
Musculoskeletal pain
Fatigue
Stiffness
Sicca symptoms
Cold-induced vasospasm
Cognitive dysfunction
Depression
Headache 
Abdominal pain
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The differential diagnosis of SLE and FM 
may be difficult because the two diseases 
have some symptoms in common (Tab. I). 
In a recent study, 15 patients with FM had 
been previously misdiagnosed as having 
connective tissue diseases, including SLE 
(47). Low antinuclear antibody (ANA) ti-
ters are commonly reported in both the gen-
eral population and FM patients, and so it 
is necessary to evaluate the clinical data in 
order to avoid misdiagnoses. Wallace et al. 
described a group of 44 patients referred for 
a rheumatologic visit because of pain and 
ANA positivity in order to rule out lupus. 
After six months of follow-up, 19 (43%) 
fulfilled the ACR criteria for SLE, and 14 
(32%) fulfilled the ACR criteria for FM (48). 
Although secondary FM is not associated 
with the disease activity, it may worsen the 
quality of life of patients with SLE, who 
may experience increased fatigue because 
of FM. Moreover, chronic fatigue without 
FM can influence their HRQoL even if it 
is not related to SLE disease activity or or-
gan damage (49). A recent study has con-
firmed that SLE patients have lower SF-36 
scores than the general population; FM is 
independently associated with a poorer 
HRQoL, underlining the need to treat pain 
promptly and accurately (50).
n	 THERAPY
The treatment of pain in SLE patients re-
quires a differential diagnosis. In particu-
lar, it is necessary to establish whether pain 
is localized or widespread, visceral or mus-
culoskeletal. The first step is to evaluate the 
SLE activity, and optimize a specific SLE 
treatment with immunosuppressive drugs 
and steroids (51, 52). 
FM symptoms in an SLE patient may be 
misinterpreted as lupus disease activity, 
thus leading to over-treatment. Once it is 
excluded that the cause of pain is not at-
tributable to the disease activity, the same 
treatment used for FM can be adminis-
tered. Analgesic drugs, such as acetamino-
phen or tramadol, can be safely used in pa-
tients with widespread pain and SLE (53). 
Anti-epileptic drugs, such as gabapentin 
and pregabalin, have been approved for the 
treatment of neuropathic pain. Pregabalin 
is also approved by the American Food and 
Drug Administration (FDA) for FM. Both 
drugs have a favorable safety and tolerabil-
ity profile (54). Low doses of tricyclic an-
tidepressants are useful in the case of mus-
culoskeletal pain and headache. Selective 
serotonin reuptake inhibitors and serotonin 
norepinephrine reuptake inhibitors, such as 
duloxetine (approved by the FDA for FM), 
can be used in SLE patients with pain and 
depression (55). In many cases non-phar-
macological treatments, such as aerobic 
exercise and cognitive behavioral therapy, 
may also be useful (56). 
In conclusion, an accurate diagnosis of 
musculoskeletal, inflammatory and SLE-
related or FM-associated pain is essential 
in order to start the right therapy and avoid 
dangerous over-treatment in SLE patients 
with co-existing widespread pain and FM. 
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